Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of DUSA Pharmaceuticals, Inc. Shareholders

Kirby McInerney LLP is investigating potential claims against the Board of Directors of DUSA Pharmaceuticals, Inc. (“DUSA” or the “Company”) (NASDAQ: DUSA) related to the proposed acquisition of the Company by Sun Pharmaceutical Industries Limited. Under the terms of the agreement, Sun Pharmaceutical will commence a tender offer to acquire all of the outstanding common stock of DUSA for $8.00 per share in cash, or approximately $230 million.

The investigation concerns whether the DUSA Board of Directors violated its fiduciary duties by agreeing to this transaction and whether the proposed $8.00 per share consideration adequately values DUSA common shares. The average analyst price target for the Company’s shares is $8.33 per share, and at least one analyst has set a price target of $9.50 per share – 17% above the proposed acquisition price.

If you are a DUSA shareholder and wish to obtain additional information, please contact J. Brandon Walker, Esq. by email at, or by telephone at (212) 699-1145 or (888) 529-4787.

Kirby McInerney LLP is a New York-based law firm concentrating in securities, shareholder, whistleblower, antitrust and consumer litigation. For additional information, please go to


Kirby McInerney LLP
J. Brandon Walker, Esq.
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here